Back to Search Start Over

A Simple and High-Throughput ELISA-Based Neutralization Assay for the Determination of Anti-Flavivirus Neutralizing Antibodies.

Authors :
Balingit, Jean Claude
Phu Ly, Minh Huong
Matsuda, Mami
Suzuki, Ryosuke
Hasebe, Futoshi
Morita, Kouichi
Moi, Meng Ling
Source :
Vaccines; Jun2020, Vol. 8 Issue 2, p297, 1p
Publication Year :
2020

Abstract

Mosquito-borne flavivirus infections, including dengue virus and Zika virus, are major public health threats globally. While the plaque reduction neutralization test (PRNT) is considered the gold standard for determining neutralizing antibody levels to flaviviruses, the assay is time-consuming and laborious. This study, therefore, aimed to develop an enzyme-linked immunosorbent assay (ELISA)-based microneutralization test (EMNT) for the detection of neutralizing antibodies to mosquito-borne flaviviruses. The inhibition of viral growth due to neutralizing antibodies was determined colorimetrically by using EMNT. Given the significance of Fcγ-receptors (FcγR) in antibody-mediated neutralization and antibody-dependent enhancement (ADE) of flavivirus infection, non-FcγR and FcγR-expressing cell lines were used in the EMNT to allow the detection of the sum of neutralizing and immune-enhancing antibody activity as the neutralizing titer. Using anti-flavivirus monoclonal antibodies and clinical samples, the utility of EMNT was evaluated by comparing the end-point titers of the EMNT and the PRNT. The correlation between EMNT and PRNT titers was strong, indicating that EMNT was robust and reproducible. The new EMNT assay combines the biological functional assessment of virus neutralization activity and the technical advantages of ELISA and, is simple, reliable, practical, and could be automated for high-throughput implementation in flavivirus surveillance studies and vaccine trials. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
2076393X
Volume :
8
Issue :
2
Database :
Complementary Index
Journal :
Vaccines
Publication Type :
Academic Journal
Accession number :
144523822
Full Text :
https://doi.org/10.3390/vaccines8020297